The expanding cardiovascular phenotype of Marfan syndrome

European Journal of Echocardiography

Volumn 10, Issue 2, 2009, Pages 213-215

  De Backer, Julie ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYTOKINE; FIBRILLIN 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA3; ACTIN BINDING PROTEIN; FIBRILLIN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ANEURYSM; AORTA ROOT; AUTOSOMAL DOMINANT DISORDER; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONNECTIVE TISSUE DISEASE; DIASTOLE; DISEASE SEVERITY; EDITORIAL; EXTRACELLULAR MATRIX; GENE MUTATION; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE DYSPLASIA; HEART RIGHT VENTRICLE FUNCTION; HUMAN; IMMUNOHISTOCHEMISTRY; MARFAN SYNDROME; MITRAL VALVE PROLAPSE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SYSTOLE; CARDIOVASCULAR DISEASES; GENETICS; HEART VENTRICLE; PATHOLOGY;

CARDIOVASCULAR DISEASES; HEART VENTRICLES; HUMANS; MARFAN SYNDROME; MICROFILAMENT PROTEINS; PHENOTYPE; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 62449258451     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jen311     Document Type: Editorial

References (30)

1. Meijboom LJ, Timmermans J, van Tintelen JP, Nollen GJ, De Backer J, van den Berg MP et al. Evaluation of left ventricular dimensions and function in Marfan's syndrome without significant valvular regurgitation. Am J Cardiol 2005;95:795-7.
2. De Backer JF, Devos D, Segers P, Matthys D, Francois K, Gillebert TC et al. Primary impairment of left ventricular function in Marfan syndrome. Int J Cardiol 2005.
3. Savolainen A, Nisula L, Keto P, Hekali P, Viitasalo M, Kaitila I et al. Left ventricular function in children with the Marfan syndrome. Eur Heart J 1994;15:625-30.
4. Das BB, Taylor AL, Yetman AT. Left ventricular diastolic dysfunction in children and young adults with Marfan syndrome. Pediatr Cardiol 2006;27:256-8.
5. De Backer JF, Devos D, Segers P, Matthys D, Francois K, Gillebert TC et al. Primary impairment of left ventricular function in Marfan syndrome. Int J Cardiol. 2006;112:353-58.
6. Judge DP, Dietz HC. Marfan's syndrome. Lancet 2005;366: 1965-76.
7. Rosenbloom J, Abrams WR, Mecham R. Extracellular matrix 4: the elastic fiber. FASEB J 1993;7:1208-18.
8. Robinson PN, Godfrey M. The molecular genetics of Marfan syndrome and related microfibrillopathies. J Med Genet 2000;37:9-25.
9. Vracko R, Thorning D, Frederickson RG. Spatial arrangements of microfibrils in myocardial scars: application of antibody to fibrillin. J Mol Cell Cardiol 1990;22:749-57.
10. Byers PH. Determination of the molecular basis of Marfan syndrome: a growth industry. J Clin Invest 2004;114:161-3.
11. Dallas SL, Keene DR, Bruder SP, Saharinen J, Sakai LY, Mundy GR et al. Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo. J Bone Miner Res 2000;15:68-81.
12. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF. Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 1995;131:539-49.
13. Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J. Latent transforming growth factor-beta binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 1999;10:99-117.
14. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003;278:2750-7.
15. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33:407-11.
16. Pereira L, Andrikopoulos K, Tian J, Lee SY, Keene DR, Ono R et al. Targeting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 1997;17:218-22.
17. Pereira L, Lee SY, Gayraud B, Andrikopoulos K, Shapiro SD, Bunton T et al. Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci USA 1999;96:3819-23.
18. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, Huso DL et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 2004;114:172-81.
19. Bunton TE, Biery NJ, Myers L, Gayraud B, Ramirez F, Dietz HC. Phenotypic alteration of vascular smooth muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res 2001;88:37-43.
20. Li RK, Li G, Mickle DA, Weisel RD, Merante F, Luss H et al. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997;96:874-81.
21. Pauschinger M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL et al. Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 1999;99:2750-6.
22. Holweg CT, Baan CC, Niesters HG, Vantrimpont PJ, Mulder PG, Maat AP et al. TGF-beta1 gene polymorphisms in patients with end-stage heart failure. J Heart Lung Transplant 2001;20:979-84.
23. Rampazzo A, Beffagna G, Nava A, Occhi G, Bauce B, Noiato M et al. Arrhythmogenic right ventricular cardiomyopathy type 1 (ARVD1): confirmation of locus assignment and mutation screening of four candidate genes. Eur J Hum Genet 2003;11:69-76.
24. Dixon IM, Hao J, Reid NL, Roth JC. Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. Cardiovasc Res 2000;46:286-97.
25. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001;103:789-91.
26. van Wamel AJ, Ruwhof C, van der Valk-Kokshoom LE, Schrier PI, van der Laarse A. The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol Cell Biochem 2001;218: 113-24.
27. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-21.
28. Brooke JH, Loeys B, Judge D, Dietz H. Treatment of severe aortic root dilatation in Marfan syndrome with angiotensin II receptor blockade. N Engl J Med 2008 (in press).
29. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC, 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358:2787-95.
30. Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, Devereux RB et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 2007;154:624-31.